undamentalytics Newsletter
Sign in

Precision Biosciences Inc cash flow statement

In fiscal 2025, Precision Biosciences Inc's operations generated −$65.8m of cash; it spent $85,000 on capital projects, leaving free cash flow of −$65.9m.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations−52−71−87−11−46−84−58−66−52
Depreciation and amortisation259987311
Stock-based pay291417191413108
Capital spending14255532000
Free cash flow−66−96−92−16−49−86−59−66−52
Free cash flow after stock pay−68−105−106−32−68−100−71−76−60
Shares issued———25495———

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: DTIL vs STRODTIL vs SPRODTIL vs EDIT

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Precision Biosciences Inc's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Precision Biosciences Inc.